isoquercetin

Small moleculeexperimental

Clinical trial activity

7 trials · 12 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
7
Phase 3
1
Phase 4
0

Earliest trial started Jun 1, 2020 (NCT04622865)

Timeline

2020s

  1. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2025

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

O=c1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12
Mol. weight
464.38 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07303894Phase 2Jan 31, 2026Memorial Sloan-Kettering Cancer Center, National Institutes of Health (NIH)
NCT06861088Phase 3Jun 30, 2025Quercis Pharma AG
NCT04733651Phase 2Feb 20, 2021Government of Nepal
NCT04474626Phase 2Dec 31, 2020Harvard University, Quercegen Pharmaceuticals
NCT04536090Phase 2Nov 30, 2020McGill University, Pharmasciences, Quercis Pharma AG, SCiAN Services, Inc.
NCT04514510Phase 2Nov 2, 2020National Heart, Lung, and Blood Institute (NHLBI)
NCT04622865Phase 2Jun 1, 2020AB Science, Aix-Marseille University
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (12)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Quercis Pharma AGFor profit2122020
AB ScienceFor profit1112020
Aix-Marseille UniversityAcademic/Hospital1012020
Government of NepalGovernment1112021
Harvard UniversityAcademic/Hospital1112020
McGill UniversityAcademic/Hospital1112020
Memorial Sloan-Kettering Cancer CenterAcademic/Hospital1112026
National Heart, Lung, and Blood Institute (NHLBI)Government1112020
National Institutes of Health (NIH)Government1012026
PharmasciencesFor profit1012020
Quercegen PharmaceuticalsFor profit1012020
SCiAN Services, Inc.For profit1012020
12 organizations
Page 1 / 1